Tae W. Kim

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 186 publications

Whole genome sequencing reveals telomere associated genomic differences between healthy and unhealthy aging in a Korean population.

Whole genome sequencing reveals telomere associated genomic differences between healthy and unhealthy aging in a Korean population.

Journal: Biogerontology

Published: June 24, 2025

Vactosertib plus pembrolizumab in patients with non-microsatellite instability-high metastatic colorectal or gastric cancer: a multicenter, phase Ib/IIa study.

Vactosertib plus pembrolizumab in patients with non-microsatellite instability-high metastatic colorectal or gastric cancer: a multicenter, phase Ib/IIa study.

Journal: Nature communications

Published: June 16, 2025

GX-I7, a long-acting IL-7, safely and effectively increased peripheral CD8+/CD4+ T cells and TILs in patients with locally advanced or metastatic solid tumours.

GX-I7, a long-acting IL-7, safely and effectively increased peripheral CD8+/CD4+ T cells and TILs in patients with locally advanced or metastatic solid tumours.

Journal: British journal of cancer

Published: October 18, 2024

CJ14939, a Novel JAK Inhibitor, Increases Oxaliplatin-induced Cell Death Through JAK/STAT Pathway in Colorectal Cancer.

CJ14939, a Novel JAK Inhibitor, Increases Oxaliplatin-induced Cell Death Through JAK/STAT Pathway in Colorectal Cancer.

Journal: Anticancer research

Published: December 30, 2021

Dynamic increase of M2 macrophages is associated with disease progression of colorectal cancers following cetuximab-based treatment.

Dynamic increase of M2 macrophages is associated with disease progression of colorectal cancers following cetuximab-based treatment.

Journal: Scientific reports

Published: July 27, 2021

Longitudinal change of genetic variations in cetuximab-treated metastatic colorectal cancer.

Longitudinal change of genetic variations in cetuximab-treated metastatic colorectal cancer.

Journal: Cancer genetics

Published: April 15, 2021

High prevalence of TP53 loss and whole-genome doubling in early-onset colorectal cancer.

High prevalence of TP53 loss and whole-genome doubling in early-onset colorectal cancer.

Journal: Experimental & molecular medicine

Published: September 28, 2020

Effectiveness of Combining Bevacizumab With First-Line Chemotherapy Regimens for Metastatic Colorectal Cancer in Real-World Practice.

Effectiveness of Combining Bevacizumab With First-Line Chemotherapy Regimens for Metastatic Colorectal Cancer in Real-World Practice.

Journal: Clinical colorectal cancer

Published: August 19, 2020

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.

Journal: Nature

Published: August 16, 2020

The Asian Approach to the Management of Gastrintestinal Cancer Patients During the COVID-19 Pandemic Era.

The Asian Approach to the Management of Gastrintestinal Cancer Patients During the COVID-19 Pandemic Era.

Journal: Clinical colorectal cancer

Published: July 09, 2020

Feasibility of a Hybrid Risk-Adapted Monitoring System in Investigator-Sponsored Trials in Cancer.

Feasibility of a Hybrid Risk-Adapted Monitoring System in Investigator-Sponsored Trials in Cancer.

Journal: Therapeutic innovation & regulatory science

Published: March 17, 2020

Chemosensitivity to HM90822, a novel synthetic IAP antagonist, is determined by p-AKT-inducible XIAP phosphorylation in human pancreatic cancer cells.

Chemosensitivity to HM90822, a novel synthetic IAP antagonist, is determined by p-AKT-inducible XIAP phosphorylation in human pancreatic cancer cells.

Journal: Investigational new drugs

Published: March 07, 2020

Showing 1-12 of 186

Last Updated: 09/26/2026